{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038098","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.531748+00:00","generated_at":"2026-05-17T20:16:35.399425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Delcath Q2 revenue jumps 210% to $24.2M; net income $2.7M vs loss; FY25 guidance raised","bullets":["Total revenue $24.2M (+210% YoY); HEPZATO KIT revenue $22.5M, CHEMOSAT $1.7M.","Net income $2.7M vs net loss $13.7M; Non-GAAP adj. EBITDA $9.8M vs loss $0.8M.","FY2025 revenue guidance raised to $93-96M; gross margins 83-85%; positive EBITDA and cashflow each quarter.","Cash and investments $81.0M, no debt; activated 3 new U.S. centers (20 total, 10 accepting referrals).","Received EU/UK authorization for clinical study of HEPZATO in metastatic colorectal cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038098","json":"https://secwatch.observer/filing/0001628280-25-038098.json","markdown":"https://secwatch.observer/filing/0001628280-25-038098.md","text":"https://secwatch.observer/filing/0001628280-25-038098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/0001628280-25-038098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828025038098/dcth-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:16:35.399425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}